CN113713063B - 一种抗肿瘤中药组合物及其制备方法和应用 - Google Patents
一种抗肿瘤中药组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN113713063B CN113713063B CN202111202552.7A CN202111202552A CN113713063B CN 113713063 B CN113713063 B CN 113713063B CN 202111202552 A CN202111202552 A CN 202111202552A CN 113713063 B CN113713063 B CN 113713063B
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- tumor
- chinese medicine
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 175
- 239000000203 mixture Substances 0.000 title claims abstract description 95
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 235000006533 astragalus Nutrition 0.000 claims abstract description 73
- 229940079593 drug Drugs 0.000 claims abstract description 70
- 239000002994 raw material Substances 0.000 claims abstract description 63
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 53
- 241000206469 Pulsatilla Species 0.000 claims abstract description 50
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 30
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 24
- 241000218691 Cupressaceae Species 0.000 claims abstract description 17
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 14
- 201000007270 liver cancer Diseases 0.000 claims abstract description 8
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 8
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 7
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 7
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims abstract description 7
- 206010029260 Neuroblastoma Diseases 0.000 claims abstract description 7
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims abstract description 7
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims abstract description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 7
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 7
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 7
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims abstract description 7
- 201000004101 esophageal cancer Diseases 0.000 claims abstract description 7
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 7
- 201000001441 melanoma Diseases 0.000 claims abstract description 7
- 201000008968 osteosarcoma Diseases 0.000 claims abstract description 7
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 4
- 201000005202 lung cancer Diseases 0.000 claims abstract description 4
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 4
- 241001061264 Astragalus Species 0.000 claims description 49
- 210000004233 talus Anatomy 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000000284 extract Substances 0.000 claims description 40
- 239000000243 solution Substances 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 20
- 241000972673 Phellodendron amurense Species 0.000 claims description 16
- 240000009022 Smilax rotundifolia Species 0.000 claims description 16
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 16
- 241000099774 Cuscuta salina Species 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 230000002829 reductive effect Effects 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 239000006188 syrup Substances 0.000 claims description 8
- 235000020357 syrup Nutrition 0.000 claims description 8
- 239000003826 tablet Substances 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- -1 decoction Substances 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 abstract description 5
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 5
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 5
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 206010067484 Adverse reaction Diseases 0.000 abstract description 2
- 230000006838 adverse reaction Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 230000005917 in vivo anti-tumor Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 159
- 241001083548 Anemone Species 0.000 description 81
- 241000699670 Mus sp. Species 0.000 description 58
- 241000699666 Mus <mouse, genus> Species 0.000 description 43
- 230000000694 effects Effects 0.000 description 36
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 35
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 30
- 150000001875 compounds Chemical class 0.000 description 30
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 30
- 229940107666 astragalus root Drugs 0.000 description 28
- 235000014347 soups Nutrition 0.000 description 28
- 241001465754 Metazoa Species 0.000 description 27
- 238000002474 experimental method Methods 0.000 description 27
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 26
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 26
- 229960003787 sorafenib Drugs 0.000 description 26
- 206010003445 Ascites Diseases 0.000 description 25
- 244000197580 Poria cocos Species 0.000 description 25
- 235000008599 Poria cocos Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 238000012360 testing method Methods 0.000 description 19
- 239000000706 filtrate Substances 0.000 description 17
- 241000123887 Pulsatilla chinensis Species 0.000 description 16
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 16
- 238000002156 mixing Methods 0.000 description 16
- 238000000605 extraction Methods 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 230000035755 proliferation Effects 0.000 description 13
- 238000001262 western blot Methods 0.000 description 13
- 229920002261 Corn starch Polymers 0.000 description 12
- 239000008120 corn starch Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
- 230000037396 body weight Effects 0.000 description 11
- 239000008101 lactose Substances 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 235000001188 Peltandra virginica Nutrition 0.000 description 10
- 229910002092 carbon dioxide Inorganic materials 0.000 description 10
- 239000006072 paste Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 9
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 8
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 8
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 8
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000004393 prognosis Methods 0.000 description 7
- 230000019491 signal transduction Effects 0.000 description 7
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 6
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 6
- 241000218202 Coptis Species 0.000 description 6
- 235000002991 Coptis groenlandica Nutrition 0.000 description 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 6
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 6
- 239000012980 RPMI-1640 medium Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 102000003814 Interleukin-10 Human genes 0.000 description 5
- 108090000174 Interleukin-10 Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000003698 anagen phase Effects 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008506 pathogenesis Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
- 229920002401 polyacrylamide Polymers 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 3
- 241000007126 Codonopsis pilosula Species 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 206010023774 Large cell lung cancer Diseases 0.000 description 3
- 244000046146 Pueraria lobata Species 0.000 description 3
- 235000010575 Pueraria lobata Nutrition 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000005352 clarification Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 101150107963 eno gene Proteins 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000003125 jurkat cell Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 description 3
- 201000009546 lung large cell carcinoma Diseases 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000012353 t test Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 241000282461 Canis lupus Species 0.000 description 2
- 108091006146 Channels Proteins 0.000 description 2
- 239000008589 Cortex Fraxini Substances 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- JLUQTCXCAFSSLD-NXEZZACHSA-N Anemonin Chemical compound C1=CC(=O)O[C@]11[C@@]2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-NXEZZACHSA-N 0.000 description 1
- JLUQTCXCAFSSLD-UHFFFAOYSA-N Anemonin Natural products C1=CC(=O)OC11C2(C=CC(=O)O2)CC1 JLUQTCXCAFSSLD-UHFFFAOYSA-N 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 241000508725 Elymus repens Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 244000236658 Paeonia lactiflora Species 0.000 description 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000004765 promyelocyte Anatomy 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
样品名称 | 浓度 | 溶剂 |
芪苓白头翁汤 | 1g/ml | 蒸馏水 |
白头翁汤 | 1g/ml | 蒸馏水 |
组别 | 药物 | 剂量 | 给药方式 | 给药频率 |
雌性组 | 芪苓白头翁汤 | 0.2ml/10g | 灌胃 | 两次 |
雄性组 | 芪苓白头翁汤 | 0.2ml/10g | 灌胃 | 两次 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111202552.7A CN113713063B (zh) | 2021-10-15 | 2021-10-15 | 一种抗肿瘤中药组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111202552.7A CN113713063B (zh) | 2021-10-15 | 2021-10-15 | 一种抗肿瘤中药组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113713063A CN113713063A (zh) | 2021-11-30 |
CN113713063B true CN113713063B (zh) | 2022-05-17 |
Family
ID=78685997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111202552.7A Active CN113713063B (zh) | 2021-10-15 | 2021-10-15 | 一种抗肿瘤中药组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113713063B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113925944B (zh) * | 2021-11-22 | 2022-09-27 | 上海市中医医院 | 一种治疗淋巴瘤的中药组合物及其制备方法和应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102100836B (zh) * | 2011-01-24 | 2012-07-04 | 四川国康药业有限公司 | 一种治疗肿瘤的药物组合物及其制备方法和用途 |
CN110384738A (zh) * | 2019-08-14 | 2019-10-29 | 河南中医药大学 | 金匮要略方白头翁汤加甘草阿胶汤水提物在制备抑制食管癌细胞药物中的应用 |
-
2021
- 2021-10-15 CN CN202111202552.7A patent/CN113713063B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN113713063A (zh) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112472729B (zh) | 香青藤在制备用于治疗人胶质瘤的药物中的应用 | |
CN108743892A (zh) | 升阳益胃汤方中药提取物的制备方法及其应用 | |
CN113713063B (zh) | 一种抗肿瘤中药组合物及其制备方法和应用 | |
KR20180003617A (ko) | 사이토메갈로바이러스 감염 장애를 치료하기 위한 의약 또는 건강 관리 제품의 제조에서의 인삼 추출물, 진세노사이드 및 진세노사이드 유도체의 용도 | |
CN100574768C (zh) | 一种抗癌药物组合物及其制备方法和用途 | |
CN101757281B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN102861148B (zh) | 一种治疗原发性痛经的中药制剂及制备方法与应用 | |
CN111840425A (zh) | 一种治疗糖尿病肾病的中药组合物及其应用 | |
CN1961898B (zh) | 一种复方半枝莲抗肿瘤药物组合物及其制备方法 | |
CN100482266C (zh) | 一种由肿节风和白花蛇舌草制成的药物组合物 | |
CN101062374B (zh) | 一种治疗癌症的中药组合物胶囊的制备方法及其产品 | |
CN108452008A (zh) | 一种包含叶下珠、云芝、丹参和紫草的中药组合物在制备抑制肝癌术后复发的药物中的应用 | |
CN100534476C (zh) | 由板蓝根和射干制成的药物组合物及其制备方法和用途 | |
CN102430009A (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN102430008A (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN101011543B (zh) | 一种新的抗肿瘤药物组合物 | |
CN1903308B (zh) | 虎眼万年青有效部位及其制备方法、药物和应用 | |
CN100382824C (zh) | 一种治疗慢性肝炎的中药及其制备方法 | |
CN106963825B (zh) | 一种治疗和/或辅助治疗骨关节疾病的药物组合物及其制备方法 | |
CN100421705C (zh) | 从纯中药制剂中提取具有改善性生活质量的复方雄蛾强肾原料药的方法 | |
CN1981812B (zh) | 一种治疗艾滋病的中药制剂及其制备方法 | |
CN110613816A (zh) | 一种复方黄芪中药组合物及制备方法和用途 | |
CN101073564B (zh) | 一种含l-谷氨酰胺的药物组合物 | |
CN105250919B (zh) | 一种用于预防和/或治疗肝疾病的中药组合物及其制备方法 | |
CN111202818A (zh) | 一种中药组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Ni Haiwen Inventor after: Zhao Yujuan Inventor before: Zhao Yujuan Inventor before: Ni Haiwen |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231212 Address after: No. 155, Hanzhong Road, Qinhuai District, Nanjing, Jiangsu 210029 Patentee after: JIANGSU PROVINCE HOSPITAL OF TCM Patentee after: NANJING OGPHARMACEUTICAL TECHNOLOGY SERVICE CO.,LTD. Address before: F6-101, Jiangsu life science and Technology Innovation Park, No. 9, Weidi Road, Qixia District, Nanjing, Jiangsu 210033 Patentee before: NANJING HIGH-WIT BIOTECHNOLOGY CO. |
|
TR01 | Transfer of patent right |